MedReleaf (TSX:LEAF) announced it became the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices for Active Pharmaceutical Ingredients.
As quoted in the press release:
MedReleaf’s wide-ranging ICH-GMP compliance certification covers the Research and Development, Production, Distribution, Processing, Selling, and Destruction of medical cannabis for its Markham facility.
Although there are a number of different GMP certifying bodies, the ICH-GMP is the globally accepted standard for the pharmaceutical industry recognized by regulatory authorities around the world including Canada, the United States, EU, Japan, Singapore and Australia.
MedReleaf’s ICH-GMP certification will support the Company’s international growth and commitment to maintaining its position as the Medical Grade Standard in a number of ways, including:
- Providing the Company with a global manufacturing practice and platform that complies with GMP requirements around the world.
- Facilitating the sale of MedReleaf products to any global market allowing the import of medical cannabis.
- Accelerating MedReleaf’s partnerships with pharmaceutical and biotech companies as the only ICH-GMP certified producer of medical cannabis that can be used in late-stage clinical trials around the world.